RegCell, Inc. is an Emeryville, California-based biotechnology company developing regulatory T-cell (Treg) therapies to restore immune tolerance in autoimmune disease and transplantation. Its epigenetic reprogramming platform builds on the discovery of Tregs by Nobel Laureate co-founder Shimon Sakaguchi, and the company was founded in Japan before redomiciling to the United States in 2025.
1
Round
1
Industry
3
Tags
Sep 15, 2026
Latest raise
Funding activity · 1 round
Sep 15, 2026
$44M
Series A
Led by Playground Global
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
